GSK plc Class Action: The Gross Law Firm Reminds GSK Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 – GSK

Core Viewpoint - GSK plc is facing a class action lawsuit related to the alleged misleading statements regarding the withdrawal of Zantac from the market and its connection to cancer risks [3][4]. Group 1: Allegations and Class Period - The class period for the lawsuit is from February 5, 2020, to August 14, 2022 [3]. - Allegations include that GSK misrepresented the reasons for removing Zantac from the market and claimed there was no evidence linking ranitidine to cancer, despite being aware of the source of NDMA for nearly 40 years [3]. Group 2: Shareholder Actions - Shareholders who purchased GSK shares during the specified class period are encouraged to register for the class action and can seek lead plaintiff status by the deadline of April 7, 2025 [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. Group 3: Law Firm's Role - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to recover losses incurred by investors due to misleading statements or omissions that inflated GSK's stock price [5].